UBS believes that BioMérieux's fundamentals are stronger at the end of the quarter than at its beginning. The analyst reiterates a buy recommendation on the stock, maintaining a price target of EUR138.
"The third quarter strengthens our conviction in our forecast of a medium-term sales CAGR of 8%, driven by Spotfire, while non-structural concerns related to influenza have now become a growth factor," UBS explains in its latest research note.
BioMérieux has announced that it now expects organic sales growth between +5.5% and +6.5% at constant exchange rates for 2025 (down from the previous guidance of +6% to +7.5%), citing a "late respiratory season."
Nevertheless, the in vitro diagnostics group has confirmed that it still expects contributive current operating income to grow between +12% and +18% at constant exchange rates, "based on nine-month profitability fully in line with the GO-28 trajectory."
